Novozymes and Novo Nordisk Partner on Enzymes
Danish companies Novozymes and Novo Nordisk Pharmatech are teaming up to develop technical enzymes to support biopharma processing. The companies aim to develop high-quality enzymatic processing aids for the regenerative medicines market, focusing on stem cell and gene therapies.
“This collaboration reinforces a shared commitment to the development of specialty enzymes. Novo Nordisk Pharmatech brings market knowledge and the required production-quality capabilities, while Novozymes brings a large enzyme library and strong R&D competencies. Together, this positions us well to create new and innovative products for this market,” said Lotte Clemmen Christensen, vice president, corporate strategy & new business development at Novozymes.
The partners expect to bring a first product to commercialization within a few years.
Author: Elaine Burridge, Freelance Journalist
Novozymes and Novo Nordisk Pharmatech are teaming up to develop best-in-class technical enzymes to support biopharma processing. The companies aim to develop high-quality enzymatic processing aids for the regenerative medicines market, focusing on stem cell and gene therapies. (c) Novozymes
